Clinical Trials Browser

Completed × OTHER × Cetuximab × Clear all

NCT01647555 2026-03-18

Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer

Head and Neck Neoplasms

NCT03370276 2026-03-10

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 1/2 Completed

95 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck, Neoplasms, Squamous Cell

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms

NCT04290546 2026-02-27

CIML NK Cell in Head & Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00556413 2026-02-05

Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT02979977 2026-02-04

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Phase 2 Completed

50 enrolled 14 charts

Squamous Cell Cancers of the Head and Neck

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT05040568 2026-01-26

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Phase 1 Completed

Gastrointestinal

Colonic Neoplasms

NCT03290937 2026-01-06

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms

NCT01827956 2025-12-29

FCR-VADS

121 enrolled 7 charts

Upper Gingival Squamous Cell Carcinoma

NCT00957411 2025-11-24

CETUXICOL

Phase 2 Completed

Uterine Cervical Neoplasms

NCT00875849 2025-09-30

AACER

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT00665392 2025-08-01

ECHO-07

Phase 2 Completed

42 enrolled 24 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Tongue Neoplasms

NCT03186326 2025-06-29

SAMCO

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT07015333 2025-06-11

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

Squamous Cell Carcinoma of Head and Neck

NCT04278092 2025-05-08

Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03428958 2025-04-23

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Phase 1/2 Completed

111 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT02934529 2025-04-16

AIO-KRK-0114

Phase 3 Completed

Gastrointestinal

Colorectal Neoplasms

NCT05217069 2025-04-16

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Phase 2 Completed

Neoplasms, Second Primary

NCT04091867 2025-02-24

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT04513951 2025-01-09

AVETRIC

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT02573493 2024-12-27

APA

Phase 2 Completed

96 enrolled 34 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00868491 2024-10-18

Induction Chemotherapy Followed by Chemoradiation With Cetuximab in Head and Neck Cancer

Phase 2 Completed

Head and Neck Neoplasms

NCT03164655 2024-10-01

SULTAN

Phase 2 Completed

Gastrointestinal

Colorectal Cancer Metastatic

NCT03422536 2024-09-04

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled 16 charts

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03667482 2024-07-23

Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Completed

Head and Neck Squamous Cell Cancer

NCT01979211 2024-02-29

Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

24 enrolled 11 charts

Head and Neck Neoplasms

NCT01588431 2024-02-14

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Phase 2 Completed

3 enrolled 7 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT01884623 2024-02-09

ELAN-UNFIT

Phase 3 Completed

Head Neck Cancer Squamous Cell Recurrent

NCT01437449 2024-01-30

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 2 Completed

27 enrolled 13 charts

Head and Neck Neoplasms

NCT02101034 2023-12-21

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Phase 1/2 Completed

96 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck

NCT02324608 2023-12-20

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Phase NA Completed

15 enrolled 11 charts

Skin Neoplasms

NCT03727724 2023-10-18

AFACET

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03914170 2023-09-26

ESTER

Gastrointestinal

Colorectal Neoplasms

NCT01004731 2023-05-25

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00593060 2023-05-24

Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT03769311 2023-05-24

Cetuximab in Head and Neck Cancer Patients

Phase 2 Completed

15 enrolled 8 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02707588 2023-02-28

PembroRad

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT04790448 2023-02-15

Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal Cancer

Phase 1/2 Completed

Gastrointestinal

Colorectal Cancer Metastatic

NCT02764593 2022-11-29

Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer

Phase 1 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00115700 2022-11-18

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Phase 3 Completed

Lymphoma, Follicular

NCT02713373 2022-10-06

Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Completed

45 enrolled 14 charts

Gastrointestinal

Colorectal Neoplasms

NCT01892527 2022-09-09

Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects

Phase 2 Completed

Gastrointestinal

Colorectal Cancer Metastatic

NCT02268695 2022-08-23

TPExtreme

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01864772 2022-08-19

ELANFIT

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT02716311 2022-08-11

ACE-Lung

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01884259 2022-05-26

HNO-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Laryngeal Diseases

NCT01553032 2022-05-25

HICARE

Phase 4 Completed

Head and Neck Neoplasms

NCT04561336 2022-05-05

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Phase 2 Completed

Gastrointestinal

Colorectal Neoplasms

NCT04508816 2022-04-04

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Phase 2 Completed

Nasopharyngeal Carcinoma